Neurológia pre prax 6/2021

Subcutaneous natalizumab in multiple sclerosis treatment

In recent years, there has been significant progress in the drug treatment of multiple sclerosis (MS). In the segment of active and high- -activity MS in particular, several new molecules, new indications and dosages or new forms of administration have been registered by the European Medicine Agency. Natalizumab was registered in the EU in 2006, and after almost 15 years, a new application form for subcutaneous administration was accepted in 2021. Bioequivalence as well as similar efficacy and safety of both routes of administration have been demonstrated in the DELIVER and REFINE clinical trials. Natalizumab SC has the potential to bring greater patient comfort and reduce the burden of infusion applications in MS treatment facilities.

Keywords: multiple sclerosis, natalizumab, subcutaneous administration.